What is the debt of Inhibrx this year?
Inhibrx has a debt level of -70.96 USD this year.
Inhibrx Debt 2024
Inhibrx Debt
-70.96 USD
Ticker
INBX
ISIN
US45720L1070
WKN
A2PQMH
In 2024, Inhibrx's total debt was -70.96 USD, a -1.18% change from the -71.8 USD total debt recorded in the previous year.
Inhibrx Aktienanalyse
What does Inhibrx do?
Inhibrx Inc is a biopharmaceutical company specializing in the development and commercialization of therapeutic antibodies. The company was founded in 2011 and is headquartered in La Jolla, California. Inhibrx's business model is based on the research and development of innovative antibodies targeting various diseases such as cancer, inflammation, autoimmune diseases, and infectious diseases. The company utilizes proprietary technologies and platforms to produce a wide range of antibodies that specifically target and block key proteins in the body. Inhibrx is divided into two business segments: the clinical development department and the research and development department. The clinical development department is responsible for conducting clinical trials of the company's antibodies. The research and development department is responsible for the development and refinement of new antibody platforms and technologies. Inhibrx has a number of products in the pipeline, including IRX-2, an antibody developed for the treatment of patients with solid tumor diseases. IRX-2 targets the PD-L1 and PD-L2 proteins, which are overexpressed by many cancer cells and help tumor cells evade immune defenses. In clinical studies, IRX-2 has shown significant reduction in tumor volume in many patients. Another promising product from Inhibrx is IRX-6, an antibody developed for the treatment of autoimmune diseases such as lupus and rheumatoid arthritis. IRX-6 targets the protein BAFF, which plays a key role in the activation of immune cells. Inhibrx has also partnered with pharmaceutical company Celgene Corporation to develop new cancer therapies. As part of the partnership, Inhibrx will utilize its proprietary antibody platforms and technologies to identify and develop new cancer therapies. Inhibrx has an excellent reputation in the industry and has been recognized multiple times for its innovative approaches and technologies. The company has secured a place among the leading biopharmaceutical companies and is expected to continue playing a significant role in the development of new therapies. Inhibrx ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding Inhibrx's Debt Structure
Inhibrx's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing Inhibrx's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to Inhibrx’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in Inhibrx’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about Inhibrx stock
What was the debt of Inhibrx compared to the previous year?
The debt of Inhibrx has increased by -1.18% compared to the previous year dropped.
What are the consequences of high debt for investors in Inhibrx?
High debt can pose a risk for investors of Inhibrx, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of Inhibrx?
Low debt means that Inhibrx has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from Inhibrx affect the company?
An increase in debt of Inhibrx can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of Inhibrx affect the company?
A reduction in debt of Inhibrx can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of Inhibrx?
Some factors that can influence the debt of Inhibrx include investments, acquisitions, operating costs, and revenue development.
Why are the debts of Inhibrx so important for investors?
The debts of Inhibrx are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can Inhibrx take to change the debt?
To change the debt, Inhibrx can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does Inhibrx pay?
Over the past 12 months, Inhibrx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Inhibrx is expected to pay a dividend of 0 USD.
What is the dividend yield of Inhibrx?
The current dividend yield of Inhibrx is .
When does Inhibrx pay dividends?
Inhibrx pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Inhibrx?
Inhibrx paid dividends every year for the past 0 years.
What is the dividend of Inhibrx?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Inhibrx located?
Inhibrx is assigned to the 'Health' sector.
Wann musste ich die Aktien von Inhibrx kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Inhibrx from 10/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/8/2024.
When did Inhibrx pay the last dividend?
The last dividend was paid out on 10/8/2024.
What was the dividend of Inhibrx in the year 2023?
In the year 2023, Inhibrx distributed 0 USD as dividends.
In which currency does Inhibrx pay out the dividend?
The dividends of Inhibrx are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Inhibrx
Our stock analysis for Inhibrx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inhibrx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
